Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking... - Abstract - UK PubMed Central

Abstract

The purpose of this study was to explore the possibility of targeted molecular therapy with anti-epidermal growth factor receptor (anti-EGFR) antibody (cetuximab) for the treatment of mucinous ovarian carcinoma. ...............These results suggest the possibility of targeted molecular therapy with cetuximab for mucinous ovarian carcinoma cells lacking a KRAS gene mutation.

abstract: Accuracy of Frozen-Section Diagnosis of Ovarian Mucinous Tumors

Conclusions:
The sensitivity of frozen-section diagnosis of LMP and malignant mucinous tumors was low. The inaccuracy of a frozen-section diagnosis of ovarian mucinous tumors may be related to a tumor size of greater than 13 cm. Increasing the number of intraoperative samples over 3 sections per case may not effectively increase the accuracy of frozen-section diagnosis in mucinous tumors.

abstract: Natural history and outcome of mucinous carcinoma of the ovary (women dx'd 1988 to 2007)

Blogger's Note: this conclusion therefore begs an obvious question

OBJECTIVE:

We performed a population-based analysis to compare the clinical characteristics of women with mucinous tumors with women with other epithelial tumors. (SEER stats)

 CONCLUSION:

Although survival for early-stage mucinous and serous tumors is similar, survival for advanced-stage mucinous neoplasms is inferior to that of serous carcinomas.